Intervention not reported
Mean FEV1 % predicted ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
Intervention not reported
Episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention leads to lower episodes of pulmonary exacerbations ‐ azithromycin prophylaxis only (high certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pneumocystis carinii pneumonia infection in children with cancer ‐ trimethoprim‐sulfamethoxazole prophylaxis only · children with cancers aged 12 years and under
The intervention probably leads to lower incidence of Pneumocystis carinii pneumonia infection in children… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention probably leads to lower mortality in children with HIV infection ‐ co‐trimoxazole… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality in children with HIV infection ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in mortality in children with HIV infection ‐ isoniazid prophylaxis only (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ co‐trimoxazole prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ co‐trimoxazole prophylaxis only (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ isoniazid prophylaxis only · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ isoniazid prophylaxis only (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of Pseudomonas infection in children with cystic fibrosis ‐ ciprofloxacin prophylaxis only · children with cystic fibrosis aged 12 years and under
The intervention showed no clear difference in incidence of Pseudomonas infection in children with cystic fibrosis… (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean FEV1 % predicted · children with cystic fibrosis aged 12 years and under
1 finding from 1 review
All‐cause mortality—same beta lactam Survival · patients with sepsis
Monotherapy showed no clear difference in all‐cause mortality—same beta lactam Survival compared with combination therapy compared (low certainty).
1 finding from 1 review
All‐cause mortality—different beta lactam · patients with sepsis
Monotherapy showed no clear difference in all‐cause mortality—different beta lactam compared with combination therapy compared (low certainty).
1 finding from 1 review
Fever clearance time · children with acute pyelonephritis
1 finding from 1 review
Increase in serum creatinine during treatment · children with acute pyelonephritis
Different dosing regimens of aminoglycosides (daily showed no clear difference in increase in serum creatinine during treatment compared with 8 hourly) (low certainty).
1 finding from 1 review
Renal parenchymal damage at 6 to 12 months: all included children with acute pyelonephritis DMSA scans · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: all included children… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review
Renal parenchymal damage at 6 to 12 months: children with renal parenchymal damage on initial DMSA · children with acute pyelonephritis
Oral showed no clear difference in renal parenchymal damage at 6 to 12 months: children with renal… compared with IV followed by oral (11 days) therapy (moderate certainty).
1 finding from 1 review
Persistent bacteriuria · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in persistent bacteriuria after treatment compared with long duration (7 to 14 days) IV therapy (low certainty).
1 finding from 1 review
Recurrent UTI within 6 months · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in recurrent UTI within 6 months compared with long duration (7 to 14 days) IV therapy (moderate certainty).
1 finding from 1 review
Persistent renal damage at 3 to 6 months: all included children with acute pyelonephritis · children with acute pyelonephritis
Short duration (3 to 4 days) showed no clear difference in persistent renal damage at 3 to 6 months: all included children with… compared with long duration (7 to 14 days) IV therapy (moderate certainty).
1 finding from 1 review